OTCMKTS:CXRXF ADVANZ PHARMA (CXRXF) Stock Price, News & Analysis $17.06 0.00 (0.00%) As of 06/10/2021 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About ADVANZ PHARMA Stock (OTCMKTS:CXRXF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ADVANZ PHARMA alerts:Sign Up Key Stats Today's Range$17.06▼$17.0650-Day Range$17.06▼$17.0652-Week Range$2.13▼$18.00Volume39 shsAverage Volume11,851 shsMarket Capitalization$834.46 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Advanz Pharma is a specialty pharmaceutical company focused on the development, acquisition and commercialization of off-patent and niche branded medicines. The firm seeks to address gaps in treatment by bringing a diverse portfolio of established pharmaceuticals to market, often targeting therapeutic areas such as endocrinology, oncology and pain management. Advanz Pharma’s strategy combines lifecycle management of legacy brands with selective investment in product improvements and regulatory filings to extend market exclusivity and patient access. The company’s product range includes hormonal therapies for endocrine disorders, pain management medicines including branded analgesics, and supportive care products used alongside oncology treatments. Advanz Pharma leverages its regulatory expertise to maintain uninterrupted supply of medicines that have limited competition, and it actively pursues approvals and registrations in multiple jurisdictions. Its commercial model emphasizes partnerships with local distributors and direct sales teams to maximize market penetration in each territory. Advanz Pharma was established in 2018 following a carve-out of certain pharmaceutical assets from a larger specialty pharma group. Since then, it has built a presence across Europe and Canada, with key markets including the United Kingdom, Germany, Italy and select Nordic countries. Headquartered in London, the company operates regional offices and collaborates with healthcare providers to support product uptake and patient education. Through its focused portfolio and agile launch capabilities, Advanz Pharma aims to sustain growth by addressing unmet needs in niche therapeutic segments.AI Generated. May Contain Errors. Read More Receive CXRXF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ADVANZ PHARMA and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CXRXF Stock News HeadlinesPHAT Phathom Pharmaceuticals, Inc.April 6, 2024 | seekingalpha.comDimerix completes ‘highly strategic’ $20m cap raise to advance ACTION3 Phase 3 trialMarch 12, 2024 | msn.comREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for yourself. Once you see what’s unfolding behind the scenes, you’ll understand why I rushed this interview and opportunity to you today. | Paradigm Press (Ad)Interim results for Dimerix’s Phase 3 trial of DXB-200 for FSGS kidney disease on track for release in March 2024February 27, 2024 | msn.comDimerix receives $10.7 million upfront payment from Advanz PharmaNovember 7, 2023 | msn.comApplied Therapeutics adds 19% on partnership with Advanz Pharma for lead assetJanuary 4, 2023 | msn.comMADE in America Act is critical for the pharmaceutical industrySeptember 27, 2022 | dallasnews.comDPolyPid to get $2.6M upfront under license deal with Advanz for D-PLEX in EuropeAugust 5, 2022 | seekingalpha.comSee More Headlines CXRXF Stock Analysis - Frequently Asked Questions How have CXRXF shares performed this year? ADVANZ PHARMA's stock was trading at $17.06 at the beginning of the year. Since then, CXRXF stock has increased by 0.0% and is now trading at $17.06. How do I buy shares of ADVANZ PHARMA? Shares of CXRXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:CXRXF CIKN/A Webwww.advanzpharma.com Phone44-20-8588-9100FaxN/AEmployees429Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$74.86 million Net Margins-15.31% Pretax MarginN/A Return on EquityN/A Return on Assets-4.38% Debt Debt-to-Equity Ratio257.04 Current Ratio2.39 Quick Ratio1.61 Sales & Book Value Annual Sales$525.58 million Price / Sales1.59 Cash FlowN/A Price / Cash FlowN/A Book Value$0.16 per share Price / Book106.63Miscellaneous Outstanding Shares48,913,000Free FloatN/AMarket Cap$834.46 million OptionableNot Optionable BetaN/A Social Links The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (OTCMKTS:CXRXF) was last updated on 9/10/2025 by MarketBeat.com Staff From Our Partners“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredWall Street Legend Issues Urgent AI Stock WarningChaikin's stepping forward with a new warning – focused on the red-hot A.I. frenzy taking the U.S. stock marke...Chaikin Analytics | SponsoredUnlock Friday's Full Potential: Two Simple Sentences that put profits in investors’ pocketsMost traders stick to the same routine each week. But a little-known market strategy has quietly delivered a 9...Eagle Publishing | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADVANZ PHARMA Corp. Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share ADVANZ PHARMA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.